Maria Fernanda Ortolani Pollini

CV Lattes ORCID

Universidade Estadual Paulista (UNESP). Campus de Araraquara. Faculdade de Ciências Farmacêuticas (FCFAR) (Institutional affiliation from the last research proposal)
Birthplace: Brazil

graduation at Farmácia e Bioquímica from Universidade Estadual Paulista Júlio de Mesquita Filho (2023). (Source: Lattes Curriculum)

News published in Agência FAPESP Newsletter about the researcher

More items Less items

TITULO

Articles published in other media outlets ( ):

More items Less items

VEICULO: TITULO (DATA)

Scholarships in Brazil

Ongoing (most recent)

Abstract
Inflammatory bowel disease (IBD) is an autoimmune disorder of unknown etiology characterized by chronic inflammation of the gastrointestinal tract (GIT). The first-line drug used in the treatment of mild to moderate IBD is the anti-inflammatory drug 5-aminosalicylic acid (5-ASA). As this drug is quickly absorbed in the first portions of the GIT and arrives in low concentrations in the col…
ROS-responsive microparticles with targeting for activated macrophages and colon-specific release of mesalazine as a potential strategy for treating inflammatory bowel disease, BP.MS

Virtual Library in numbers * Updated data on July 19, 2025

Total / Available in English

1 / 1	Ongoing scholarships in Brazil

Associated processes

Most frequent collaborators in research granted by FAPESP

Andréia Bagliotti Meneguin

Keywords used by the researcher

Health Sciences Pharmacy

Please report errors on the page using this form.

Short URL

Abstract